Article
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 18 6679
(30) Sparano, J. A.; Bernardo, P.; Stephenson, P.; Gradishar, W. J.;
Ingle, J. N.; Zucker, S.; Davidson, N. E. Randomized phase III trial
of marimastat versus placebo in patients with metastatic breast
cancer who have responding or stable disease after first-line
chemotherapy: Eastern Cooperative Oncology Group Trial
E2196. J. Clin. Oncol. 2004, 22, 4683–4690.
(31) Lara, P. N., Jr.; Stadler, W. M.; Longmate, J.; Quinn, D. I.;
Wexler, J.; Van Loan, M.; Twardowski, P.; Gumerlock, P. H.;
Vogelzang, N. J.; Vokes, E. E.; Lenz, H. J.; Doroshow, J. H.;
Gandara, D. R. A randomized phase II Trial of the matrix
metalloproteinase inhibitor BMS-275291 in hormone-refractory
prostate cancer patients with bone metastases. Clin. Cancer Res.
2006, 12, 1556–1563.
(32) Brinker, B. T.; Krown, S. E.; Lee, J. Y.; Cesarman, E.; Chadburn,
A.; Kaplan, L. D.; Henry, D. H.; Von Roenn, J. H. Phase 1/2 trial
of BMS-275291 in patients with human immunodeficiency virus-
related Kaposi sarcoma: a multicenter trial of the AIDS malig-
nancy consortium. Cancer (Hoboken, NJ, U.S.) 2008, 112, 1083–
1088.
(33) Miller, K. D.; Saphner, T. J.; Waterhouse, D. M.; Chen, T.-T.;
Rush-Taylor, A.; Sparano, J. A.; Wolff, A. C.; Cobleigh, M. A.;
Galbraith, S.; Sledge, G. W. A randomized phase II feasibility trial
of BMS-275291 in patients with early stage breast cancer. Clin.
Cancer Res. 2004, 10, 1971–1975.
(34) Bissett, D.; O’Byrne, K. J.; von Pawel, J.; Gatzemeier, U.; Price, A.;
Nicolson, M.; Mercier, R.; Mazabel, E.; Penning, C.; Zhang,
M. H.; Collier, M. A.; Shepherd, F. A. Phase III study of matrix
metalloproteinase inhibitor prinomastat in non-small-cell lung
cancer. J. Clin. Oncol. 2005, 23, 842–849.
(35) Hudson, M. P.; Armstrong, P. W.; Ruzyllo, W.; Brum, J.; Cusmano,
L.; Krzeski, P.; Lyon, R.; Quinones, M.; Theroux, P.; Sydlowski, D.;
Kim, H. E.; Garcia, M. J.; Jaber, W. A.; Weaver, W. D. Effects of
Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Pre-
vent Ventricular Remodeling After Myocardial Infarction. J. Am.
Coll. Cardiol. 2006, 48, 15–20.
(36) Yarbrough, W. M.; Mukherjee, R.; Escobar, G. P.; Mingoia,
J. T.; Sample, J. A.; Hendrick, J. W.; Dowdy, K. B.; McLean,
J. E.; Lowry, A. S.; O’Neill, T. P.; Spinale, F. G. Selective Targe-
ting and Timing of Matrix Metalloproteinase Inhibition in Post-
Myocardial Infarction Remodeling. Circulation 2003, 108, 1753–
1759.
Stehle, N.; Swearingen, C.; Becker, D. P. MMP-13 selective
isonipecotamide R-sulfone hydroxamates. Bioorg. Med. Chem.
Lett. 2010, 20, 3561–3564.
(46) van de Waterbeemd, H.; Testa, B. In Drug Bioavailability: Estima-
tion of Solubility, Permeability, Absorption and Bioavailability;
€
Strauss GmbH: Morlenbach, Germany, 2009; pp 458.
(47) Silverman, R. B. Lead Modification: Drug Design and Develop-
ment. In The Organic Chemistry of Drug Design and Drug Action;
Elsevier Academic Press: New York, 2004; pp 62-65.
(48) Mistryukov, E. A.; Aronova, N. I. Basicity of amines of the
piperidine series and dependence of basicity on steric and polar
factors. Izv. Akad. Nauk SSSR, Ser. Khim. 1967, 789–793.
(49) Gillaspy, M.; Lefker, B. A.; Hada, W. A.; Hoover, D. J. A simple
method for the formation of cyclopropylamines: the first syn-
thesis of tricyclopropylamine. Tetrahedron Lett. 1995, 36, 7399–
7402.
(50) Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.;
Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase
for drugs, drug actions and drug targets. Nucleic Acids Res. 2008,
36, D901–D906.
(51) Kageyama, S.; Anderson, B. D.; Hoesterey, B. L.; Hayashi, H.;
Kiso, Y.; Flora, K. P.; Mitsuya, H. Protein binding of human
immunodeficiency virus protease inhibitor KNI-272 and alteration
of its in vitro antiretroviral activity in the presence of high
concentrations of proteins. Antimicrob. Agents Chemother. 1994,
38, 1107–1111.
(52) Hagmann, W. K. The Many Roles for Fluorine in Medicinal
Chemistry. J. Med. Chem. 2008, 51, 4359–4369.
(53) Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Luther, M. A.; Weigl, D.;
McGeehan, G.; Lambert, M. H.; Jordan, S. R. Structural analysis
of the catalytic domain of human fibroblast collagenase. Ann. N.Y.
Acad. Sci. 1994, 732, 375–378.
(54) Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D’Arcy, A.;
Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J.
Structure of the catalytic domain of human fibroblast collagenase
complexed with an inhibitor. Nat. Struct. Biol. 1994, 1, 106–110.
(55) Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.;
Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.;
Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -
13 reveal the structural basis for selectivity of collagenase inhibi-
tors. Nature Struct. Biol. 1999, 6, 217–221.
(37) Krzeski, P.; Buckland-Wright, C.; Balint, G.; Cline, G. A.; Stoner,
K.; Lyon, R.; Beary, J.; Aronstein, W. S.; Spector, T. D. Develop-
ment of musculoskeletal toxicity without clear benefit after admin-
istration of PG-116800, a matrix metalloproteinase inhibitor,
to patients with knee osteoarthritis: a randomized, 12-month,
double-blind, placebo-controlled study. Arthritis Res. Ther. 2007,
9, R109.
(38) Becker, D. P.; Barta, T. E.; Bedell, L.; DeCrescenzo, G.; Freskos,
J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Mischke,
B.; Munie, G. E.; Swearingen, C.; Villamil, C. I. R-Amino-R-
sulphone hydroxamates as potent MMP-13 inhibitors that spare
MMP-1 Bioorg. Med. Chem. Lett. 2001, 11, 2719-2722.
(39) Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.;
Hockerman, S. L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C.
R-Alkyl-R-amino-R-sulphone hydroxamates as potent MMP inhibi-
tors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2723-2725.
(40) Lollini, L.; Haller, J.; Eugui, E. M.; Womble, S. W.; Martin, R.;
Campbell, J. Disease modification by RS-130830, a collagenase-3
selective inhibitor, in experimental osteoarthritis (OA). Arthritis
Rheum. 1997, 40 (Suppl S87), 341.
(56) Howard, J. A. K.; Hoy, V. J.; O’Hagan, D.; Smith, G. T. How good
is fluorine as a hydrogen bond acceptor? Tetrahedron 1996, 52,
12613–12622.
(57) Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.;
Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.;
Wood, A.; Varki, N. M.; Appelt, K. Broad antitumor and anti-
angiogenic activities of AG3340, a potent and selective MMP
inhibitor undergoing advanced oncology clinical trials. Ann. N.Y.
Acad. Sci. 1999, 878, 236–270.
(58) Bottomley, K. M.; Borkakoti, N.; Bradshaw, D.; Brown, P. A.;
Broadhurst, M. J.; Budd, J. M.; Elliott, L.; Eyers, P.; Hallam, T. J.;
Handa, B. K.; Hill, C. H.; James, M.; Lahm, H.; Lawton, G.;
Merritt, J. E.; Nixon, J. S.; Rothlisberger, U.; Whittle, A.; Johnson,
W. H. Inhibition of bovine nasal cartilage degradation by selective
matrix metalloproteinase inhibitors. Biochem. J. 1997, 323, 483–
488.
(59) Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne,
R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.;
Tschesche, H.; Chen, J.; Van Wart, H.; Poole, A. R. Enhanced
cleavage of type II collagen by collagenases in osteoarthritic
articular cartilage. J. Clin. Invest. 1997, 99, 1534–1545.
(60) Pfeffer, M. A.; Pfeffer, J. M.; Fishbein, M. C.; Fletcher, P. J.;
Spadaro, J.; Kloner, R. A.; Braunwald, E. Myocardial infarct size
and ventricular function in rats. Circ. Res. 1979, 44, 503–512.
(61) Fletcher, P. J.; Pfeffer, J. M.; Pfeffer, M. A.; Braunwald, E. Left
ventricular diastolic pressure-volume relations in rats with healed
myocardial infarction. Effects on systolic function. Circ. Res. 1981,
49, 618–626.
(41) Close, D. R. Matrix metalloproteinase inhibitors in rheumatic
diseases. Ann. Rheum. Dis. 2001, 60, iii62–iii67.
(42) Becker, D. P.; Villamil, C. I.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.;
DeCrescenzo, G. A.; Freskos, J. N.; Getman, D. P.; Hockerman, S.;
Heintz, R.;Howard, S. C.; Li, M. H.; McDonald, J. J.; Carron, C. P.;
Funckes-Shippy, C. L.; Mehta, P. P.; Munie, G. E.; Swearingen,
C. A. Synthesis and structure-activity relationships of β- and
R-piperidine sulfone hydroxamic acid matrix metalloproteinase
inhibitors with oral antitumor efficacy. J. Med. Chem. 2005, 48,
6713–6730.
(43) Samaritoni, J. G.; Babbitt, G. E. Synthesis of 2-(4-quinazoli-
nyl)ethyl sulfides via addition of thiols to 4-vinylquinazolines.
J. Heterocycl. Chem. 1997, 34, 1263–1266.
(44) Kolodziej, S. A.; Hockerman, S. L.; Boehm, T. L.; Carroll, J. N.;
DeCrescenzo, G. A.; McDonald, J. J.; Mischke, D. A.; Munie,
G. E.; Fletcher, T. R.; Rico, J. G.; Stehle, N. W.; Swearingen, C.;
Becker, D. P. Orally bioavailable dual MMP-1/MMP-14 sparing,
MMP-13 selective R-sulfone hydroxamates. Bioorg. Med. Chem.
Lett. 2010, 20, 3557–3560.
(62) Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.;
Kuznetsov, S. A.; Mankani, M.; Robey, P. G.; Poole, A. R.;
Pidoux, I.; Ward, J. M.; Birkedal-Hansen, H. MT1-MMP-deficient
mice develop dwarfism, osteopenia, arthritis, and connective tissue
disease due to inadequate collagen turnover. Cell (Cambridge, MA,
U. S.) 1999, 99, 81–92.
(63) Zhou, Z.; Apte, S. S.; Soininen, R.; Cao, R.; Baaklini, G. Y.;
Rauser, R. W.; Wang, J.; Cao, Y.; Tryggvason, K. Impaired
endochondral ossification and angiogenesis in mice deficient in
membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci.
U.S.A. 2000, 97, 4052–4057.
(45) Kolodziej, S. A.; Hockerman, S. L.; DeCrescenzo, G. A.;
(64) Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans,
McDonald, J. J.; Mischke, D. A.; Munie, G. E.; Fletcher, T. R.;
N.; Chang, E.; Tao, Q.; Vanhove, M.; Lejeune, A.; van Gool, R.;